SCHEMBL3282912

SCHEMBL3282912

COc1ccccc1C(=O)Cc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.63
TP53 P04637 2/20 0.59
USP2 O75604 1/20 0.59
GLA P06280 1/20 0.59
HPGD P15428 1/20 0.59
CTSD P07339 1/20 0.54
RAB9A P51151 3/20 0.54
GPR52 Q9Y2T5 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
KMT2A Q03164 2/20 0.53
HTT P42858 2/20 0.53
ALDH1A1 P00352 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MEN1 O00255 1/20 0.53
LMNA P02545 2/20 0.51
IDO1 P14902 1/20 0.51
TDO2 P48775 1/20 0.51
CTNNB1 P35222 1/20 0.51
WNT3A P56704 1/20 0.51
HDAC8 Q9BY41 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29861033 1.00 NPC1 (0.63) NPC1TP53USP2GLAHPGD
SCHEMBL19419913 0.90 TP53 (0.56) NPC1TP53USP2GLAHPGD
SCHEMBL6281987 0.87 POLB (0.63) NPC1TP53USP2GLAHPGD
SCHEMBL1276013 0.87 NPC1 (0.60) NPC1TP53USP2GLAHPGD
Bromide SCHEMBL8370980 0.85 POLB (0.62) NPC1TP53USP2GLAHPGD
SCHEMBL8968394 0.84 NPC1 (0.50) NPC1TP53USP2GLAHPGD
SCHEMBL6203601 0.83 ABCB1 (0.62) NPC1TP53GLAHPGDRAB9A
SCHEMBL8968389 0.83 NPC1 (0.49) NPC1TP53USP2GLAHPGD
SCHEMBL17637149 0.82 HSD11B1 (0.63) NPC1TP53USP2RAB9ASMN1; SMN2
SCHEMBL6151260 0.82 USP2 (0.47) NPC1TP53USP2HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113755862-B Method for preparing aromatic alpha-diketone compound by electrochemical oxidation 西南大学 2022-08-19 CN claimed
CN-113755862-A Method for preparing aromatic alpha-diketone compound by electrochemical oxidation 西南大学 2021-12-07 CN claimed
CN-113755862-B Method for preparing aromatic alpha-diketone compound by electrochemical oxidation 西南大学 2022-08-19 CN disclosed
CN-113755862-A Method for preparing aromatic alpha-diketone compound by electrochemical oxidation 西南大学 2021-12-07 CN disclosed
US-20180022693-A1 COMPOUNDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2018-01-25 US disclosed
US-20180022693-A1 COMPOUNDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2018-01-25 US disclosed
WO-2017106930-A1 COMPOUNDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2017-06-29 WO disclosed
EP-2018364-B1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN INC (US) 2013-08-21 EP disclosed
US-7709507-B2 Therapeutic fluoroethyl ureas ALLERGAN, INC. (US) 2010-05-04 US disclosed
EP-2018364-A1 THERAPEUTIC FLUOROETHYL UREAS Allergan, Inc. (US) 2009-01-28 EP disclosed
WO-2007137029-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. (US) 2007-11-29 WO disclosed
US-20070270498-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. 2007-11-22 US disclosed
WO-2007044796-A2 PYRIDAZINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2007-04-19 WO disclosed
WO-2007044796-A2 PYRIDAZINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2007-04-19 WO disclosed
EP-1032568-A4 PROCESS FOR THE PREPARATION OF ISOFLAVONES UNIV MICHIGAN STATE (US) 2003-03-05 EP disclosed
EP-1032568-A1 PROCESS FOR THE PREPARATION OF ISOFLAVONES MICHIGAN STATE UNIVERSITY (US) 2000-09-06 EP disclosed
WO-2000019994-A9 ESTROGEN RECEPTOR LIGANDS UNIV ILLINOIS (US) 2000-08-31 WO disclosed
WO-2000015627-A1 PROCESS FOR THE PREPARATION OF ISOFLAVONES MICHIGAN STATE UNIVERSITY (US) 2000-03-23 WO disclosed
EP-0221368-A2 Substituted 1,1,2-triphenyl-1-butene ASTA Pharma Aktiengesellschaft (DE) 1987-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022693-A1 COMPOUNDS ERCC4, NQO1, ERCC5 NPC1 316/4885TP53 2396/4885USP2 4764/4885
US-20070270498-A1 THERAPEUTIC FLUOROETHYL UREAS SLC14A1, MAPT, UTS2R NPC1 288/4885TP53 154/4885USP2 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.